Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Rucaparib

Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research[1][2][3][4].

Product Specifications

CAS Number

[283173-50-2]

Product Name Alternative

AG014699; PF-01367338

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rucaparib.html

Concentration

10mM

Purity

99.97

Solubility

DMSO : 70 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC2=C3C(CCNC2=O)=C(C4=CC=C(CNC)C=C4)NC3=C1

Molecular Formula

C19H18FN3O

Molecular Weight

323.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Thomas HD, et al. Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther, 2007, 6 (3), 945-956.|[2]Hunter JE, et al. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene, 2012, 31 (2), 251-264.|[3]Daniel RA, et al. Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res, 2009, 15 (4), 1241-1249.|[4]Matt Shirley, et al. Rucaparib: A Review in Ovarian Cancer. Target Oncol. 2019 Apr;14 (2) :237-246.|[5]J Murray, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014 Apr 15;110 (8) :1977-84.|[6]Jianneng Li, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Sci Transl Med. 2021 May 26;13 (595) :eabe8226.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

PARP1; PARP2; PARP3

Citation 01

Aging (Albany NY) . 2021 Jan 20;13 (3) :4242-4257.|Am J Cancer Res. 2020 Aug 1;10 (8) :2649-2676.|Am J Cancer Res. 2024 Jan 15;14 (1) :378-389.|bioRxiv. 2023 Feb 6:2023.02.06.527366.|bioRxiv. 2023 Feb 7:2023.02.07.527369.|bioRxiv. 2024 Jul 10:2024.07.09.602803.|bioRxiv. 2024 Sep 19:2024.09.19.613696.|BMC Cancer. 2022 Mar 23;22 (1) :312.|Cancers (Basel) . 2024 Nov 5;16 (22) :3728.|Clin Cancer Res. 2017 Feb 15;23 (4) :1001-1011. |DNA Repair. 2019 Jan:73:64-70.|Eur J Nucl Med Mol Imaging. 2024 Nov;51 (13) :4099-4110.|FASEB J. 2022 Jul;36 (7) :e22418.|Front Oncol. 2021 Jul 9:11:681441.|Gene. 2020 Oct 30;759:145000.|Genes Dis. 2023 Apr 12;11 (2) :993-1008.|Int J Mol Sci. 2020 Feb 11;21 (4) :1185.|JCI Insight. 2023 Nov 8;8 (21) :e165268.|Mol Cancer Ther. 2024 Oct 1;23 (10) :1404-1417.|Mol Cancer Ther. 2025 Jul 2.|Nat Commun. 2025 Jun 2;16 (1) :5126.|Nat Methods. 2023 Sep;20 (9) :1388-1399.|Neoplasia. 2025 May:63:101152.|Neurooncol Adv. 2023 Feb 10;5 (1) :vdad010.|Patent. US20180263995A1.|Patent. US20180362972A1.|Research Square Preprint. 2024 Nov 06.|Research Square Print. September 20th, 2022.|Research Square Print. September 22nd, 2022.|Sci Adv. 2022 Feb 18;8 (7) :eabl9794.|Sci Adv. Sci Adv. 2025 Apr 25;11 (17) :eadu0847.|Sci Immunol. 2024 Mar 15;9 (93) :eadj7238.|Sci Transl Med. 2021 May 26;13 (595) :eabe8226.|Talanta. 2018 Apr 1:180:127-132.|Theranostics. 2020 Jul 25;10 (21) :9477-9494. |Analyst. 2018 May 29;143 (11) :2501-2507.|Biochem Biophys Res Commun. 28 September 2021.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Nat Cell Biol. 2024 Sep;26 (9) :1545-1557.|Patent. US20200078369A1|Patent. US20200129476A1|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Sens Actuators B Chem. 2018 Nov 10; 273:1047-1053. |Sens Actuators B Chem. 2018, 259: 565-572.|J Med Chem. 2023 Mar 23;66 (6) :4106-4130.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Vom1r49 (NM_001008920) Rat Tagged ORF Clone

RR202114 10 µg

Vom1r49 (NM_001008920) Rat Tagged ORF Clone

Ask

Pwwp2a (NM_027557) Mouse Tagged ORF Clone

MR217986 10 µg

Pwwp2a (NM_027557) Mouse Tagged ORF Clone

Ask

Lentiviral human ATG16L2 sgRNA gene knockout kit - Lentiviral human ATG16L2 sgRNA gene knockout kit (25)

GTR15370860 1 Vial

Lentiviral human ATG16L2 sgRNA gene knockout kit - Lentiviral human ATG16L2 sgRNA gene knockout kit (25)

Ask

Rabbit anti-Chk2 IHC Antibody, Affinity Purified

1HC-00043-T 5 µg

Rabbit anti-Chk2 IHC Antibody, Affinity Purified

Ask